Efficacy and safety of laquinimod in multiple sclerosis: current status.

abstract：:The treatment of neuropathic pain is difficult. Oral pharmaceuticals have significant side effects, and treatment efficacy tends to be modest. The use of topical analgesics reduces the potential for systemic side effects and allows direct application of medications to the area of pain. The natural spicy substance, cap...

journal_title：Therapeutic advances in neurological disorders

authors： Peppin JF,Pappagallo M

更新日期：2014-01-01 00:00:00

abstract：:Neuromyelitis optica (NMO) is an inflammatory demyelinating disease that largely affects optic nerves and spinal cord. Recent studies have identified an elevation of serum anti-aquaporin 4 antibody as a hallmark of NMO. Typical cases of NMO significantly differ from multiple sclerosis (MS) in immunological markers, hi...

journal_title：Therapeutic advances in neurological disorders

authors： Okamoto T,Ogawa M,Lin Y,Murata M,Miyake S,Yamamura T

更新日期：2008-07-01 00:00:00

abstract：:Dabigatran is increasingly being used in clinical practice for the thromboprophylaxis in atrial fibrillation as a convenient therapy that needs no drug level monitoring. However, analysis of the data of the same clinical trial that led to the adoption of dabigatran in fixed-dosing regimens has indicated a small subgro...

journal_title：Therapeutic advances in neurological disorders

authors： Safouris A,Triantafyllou N,Parissis J,Tsivgoulis G

更新日期：2015-11-01 00:00:00

abstract：:More than 30% of epilepsy patients remain refractory despite the advent of new antiepileptic drugs (AEDs) over two decades. Although a small percentage of these refractory patients may become seizure free when a new AED is added, combined administration of AEDs or the application of novel AEDs is the most common thera...

journal_title：Therapeutic advances in neurological disorders

authors： Chung SS

更新日期：2010-03-01 00:00:00

abstract：:B cells play a central role in the pathogenesis in multiple sclerosis (MS), being involved in the activation of proinflammatory T cells, secretion of proinflammatory cytokines, and production of autoantibodies directed against myelin. Hence, the usage of B-cell-depleting monoclonal antibodies as therapy for autoimmune...

journal_title：Therapeutic advances in neurological disorders

authors： Sorensen PS,Blinkenberg M

更新日期：2016-01-01 00:00:00

abstract：:Over 320 years after Thomas Sydenham described the condition labelled Sydenham's chorea, it remains poorly understood. The disorder is an antineuronal antibody-mediated neuropsychiatric disorder caused by a poststreptococcal, autoimmune condition affecting control of movement, mood, behaviour and potentially the heart...

journal_title：Therapeutic advances in neurological disorders

authors： Walker KG,Wilmshurst JM

更新日期：2010-09-01 00:00:00

abstract：:Brain imaging is increasingly used to support clinicians in diagnosing multiple sclerosis (MS) and monitoring its progression. However, the role of magnetic resonance imaging (MRI) in MS goes far beyond its clinical application. Indeed, advanced imaging techniques have helped to detect different components of MS patho...

journal_title：Therapeutic advances in neurological disorders

authors： Cortese R,Collorone S,Ciccarelli O,Toosy AT

更新日期：2019-06-27 00:00:00

abstract：:Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability in the subset of MS patients with Expanded Disability Status Scale 4-7. Recent responder subgroup analyses in the phase II...

journal_title：Therapeutic advances in neurological disorders

authors： Albrecht P,Bjørnå IK,Brassat D,Farrell R,Feys P,Hobart J,Hupperts R,Linnebank M,Magdič J,Oreja-Guevara C,Pozzilli C,Salgado AV,Ziemssen T

更新日期：2018-10-05 00:00:00

abstract：:Stroke is the fifth leading cause of death and the most frequent cause of disability worldwide. Currently, stroke diagnosis is based on neuroimaging; therefore, the lack of a rapid tool to diagnose stroke is still a major concern. In addition, therapeutic approaches to combat ischemic stroke are still scarce, since th...

journal_title：Therapeutic advances in neurological disorders

authors： Ramiro L,Simats A,García-Berrocoso T,Montaner J

更新日期：2018-08-06 00:00:00

abstract：:Until the early 1990s, a limited number of antiepileptic drugs (AEDs) were available. Since then, a large variety of new AEDs have been developed and introduced, several of them offering new modes of action. One of these new AED families is described and reviewed in this article. Levetiracetam (LEV) and brivaracetam (...

journal_title：Therapeutic advances in neurological disorders

authors： Steinhoff BJ,Staack AM

更新日期：2019-09-09 00:00:00

abstract：BACKGROUND:The aim of this study was to analyse registry data of seizure outcome and adverse events (AEs) for perampanel as add-on therapy in patients with focal epilepsy since its approval in 2012 for adjunctive treatment of focal epilepsy in patients ⩾12 years. METHOD:A retrospective 2-year chart review of all patie...

journal_title：Therapeutic advances in neurological disorders

authors： Rohracher A,Kalss G,Leitinger M,Granbichler C,Deak I,Dobesberger J,Kuchukhidze G,Thomschewski A,Höfler J,Trinka E

更新日期：2016-11-01 00:00:00

abstract：:The World Wide Web is increasingly used in therapeutic settings. In this regard, internet-based interventions have proven effective in ameliorating several health behaviors, amongst them physical activity behavior. Internet-delivered interventions have shown positive effects on physical activity and physical function ...

journal_title：Therapeutic advances in neurological disorders

authors： Tallner A,Pfeifer K,Mäurer M

更新日期：2016-07-01 00:00:00

abstract：:Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system. Demyelinization of nerve fibres not only affects the motor and sensory systems functionally, but may also cause psychopathological signs and symptoms. In addition to the psychiatric manifestations of MS, many patients have reacti...

journal_title：Therapeutic advances in neurological disorders

authors： Haussleiter IS,Brüne M,Juckel G

更新日期：2009-01-01 00:00:00

abstract：OBJECTIVE:Intracranial aneurysms (IAs) require deliberately selected treatment strategies as they are incrementally found prior to rupture and deleterious subarachnoid haemorrhage (SAH). Multiple and recurrent aneurysms necessitate both neurointerventionalists and neurosurgeons to optimize aneurysmal occlusion in an in...

journal_title：Therapeutic advances in neurological disorders

authors： Mueller OM,Schlamann M,Mueller D,Sandalcioglu IE,Forsting M,Sure U

更新日期：2011-09-01 00:00:00

abstract：Background:Gastrointestinal (GI) events are common adverse events (AEs) associated with delayed-release dimethyl fumarate (DMF), an approved treatment for relapsing-remitting multiple sclerosis (RRMS). The objective of the TOLERATE study was to evaluate GI tolerability and GI mitigation via symptomatic therapies in pat...

journal_title：Therapeutic advances in neurological disorders

authors： Gold R,Schlegel E,Elias-Hamp B,Albert C,Schmidt S,Tackenberg B,Xiao J,Schaak T,Salmen HC

更新日期：2018-04-18 00:00:00

abstract：:Natalizumab is approved for the treatment of patients with relapsing-remitting multiple sclerosis who have failed first-line treatment with traditional disease-modifying therapies or who have highly active disease. The drug has proved highly effective, both in a clinical trial setting and in clinical practice, with ma...

journal_title：Therapeutic advances in neurological disorders

authors： Fernández O

更新日期：2013-03-01 00:00:00

abstract：Background:No evidence of disease activity (NEDA) is a composite measurement, incorporating clinical and magnetic resonance imaging (MRI) elements of disease activity to sensitively evaluate the therapeutic efficacy of treatments for relapsing-remitting multiple sclerosis (RRMS). Objective:To assess the NEDA status of...

journal_title：Therapeutic advances in neurological disorders

authors： Arnold DL,Shang S,Dong Q,Meergans M,Naylor ML

更新日期：2018-08-28 00:00:00

abstract：:Since the approval in 2010 of fingolimod 0.5 mg (Gilenya; Novartis Pharma AG, Basel, Switzerland) in the USA as an oral therapy for relapsing forms of multiple sclerosis, long-term clinical experience with this therapy has been increasing. This review provides a summary of the cumulative dataset from clinical trials a...

journal_title：Therapeutic advances in neurological disorders

authors： Khatri BO

更新日期：2016-03-01 00:00:00

abstract：:Superficial temporal artery-middle cerebral artery anastomosis is generally considered as an effective method in improving damage associated with intracerebral occlusions in moyamoya disease. Hemodynamic changes caused by revascularization are the cause of many postoperative complications. Of the 186 consecutive surge...

journal_title：Therapeutic advances in neurological disorders

authors： Yu J,Hu M,Yi L,Zhou K,Zhang J,Chen J

更新日期：2019-09-25 00:00:00

abstract：:Neuroinflammation is one of the key components contributing to the devastating outcome of ischemic stroke. Starting with stroke onset, inflammatory processes contribute both to cell damage and tissue remodeling. The early release of alarmins triggers the upregulation of multiple proinflammatory cytokines, resulting in...

journal_title：Therapeutic advances in neurological disorders

authors： Dzyubenko E,Manrique-Castano D,Kleinschnitz C,Faissner A,Hermann DM

更新日期：2018-12-17 00:00:00

abstract：:Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy has been considered a novel central nervous system autoimmune disease characterized by relapse and responsiveness to corticosteroid with a specific GFAP-Immunoglobulin G (IgG) being noted in cerebrospinal fluid. We report the case of a 21-year-old girl p...

journal_title：Therapeutic advances in neurological disorders

authors： Li XL,Han J,Zhao HT,Long YM,Zhang BW,Wang HY

更新日期：2020-06-03 00:00:00

abstract：:The BEtaferon®/BEtaseron® in Newly Emerging MS For Initial Treatment (BENEFIT) trial assessed the efficacy of early versus delayed treatment with interferon beta-1b for patients with clinically isolated syndrome (CIS). Patients were randomly assigned to receive either interferon beta-1b 250 μg every other day (early t...

journal_title：Therapeutic advances in neurological disorders

authors： Freedman MS

更新日期：2014-11-01 00:00:00

abstract：:Ehlers-Danlos syndrome (EDS) is a heterogeneous heritable connective tissue disorder with various neurological manifestations, including chronic pain. The neurological manifestations in EDS are often regarded as being caused by the associated musculoskeletal disorders or polyneuropathy. Here, we present two patients w...

journal_title：Therapeutic advances in neurological disorders

authors： Araki M,Lin Y,Ono H,Sato W,Yamamura T

更新日期：2018-08-18 00:00:00

abstract：Background:To investigate outcome and toxicity of high-dose systemic methotrexate (HDMTX)-based polychemotherapy and intracerebroventricular (ICV) chemotherapy via an Ommaya reservoir in elderly patients with primary central nervous system lymphoma (PCNSL). Methods:We performed a retrospective analysis on patients ⩾65...

journal_title：Therapeutic advances in neurological disorders

authors： Seidel S,Kowalski T,Margold M,Baraniskin A,Schroers R,Martus P,Schlegel U

更新日期：2020-10-07 00:00:00

abstract：:Chronic migraine (CM) is a severely disabling neurological condition characterized by episodes of pulsating unilateral or bilateral headache. The United States Food and Drug Administration (FDA) approved onabotulinumtoxinA (Botox®) for the prophylactic treatment of CM in 2010. It has been shown that onabotulinumtoxinA...

journal_title：Therapeutic advances in neurological disorders

authors： Escher CM,Paracka L,Dressler D,Kollewe K

更新日期：2017-02-01 00:00:00

abstract：:Experimental models of Parkinson's disease (PD) are of great importance for improving the design of future clinical trials. Various neurotoxic models are available, including 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), paraquat and rotenone. However, no model is considered perfect;...

journal_title：Therapeutic advances in neurological disorders

authors： Salama M,Arias-Carrión O

更新日期：2011-11-01 00:00:00

abstract：Background:Although the pathogenesis of myasthenia gravis (MG) is well known, prognostic markers are not yet available. We assessed the utility of anti-acetylcholine receptor (AChR) antibody (AChR-ab) titer and concentration of C3, C4, and C5a as potential severity biomarkers in MG. Methods:Levels of C3, C4, C5a, and ...

journal_title：Therapeutic advances in neurological disorders

authors： Aguirre F,Manin A,Fernandez VC,Justo ME,Leoni J,Paz ML,Villa AM

更新日期：2020-08-10 00:00:00

abstract：:A first step in evaluating the use of computers in language therapy for individuals with aphasia is to establish the treatment as active in small groups prior to large-scale clinical trials. The present study evaluated a comprehensive computer-based language therapy program in a group of eight individuals with chronic...

journal_title：Therapeutic advances in neurological disorders

authors： Archibald LM,Orange JB,Jamieson DJ

更新日期：2009-09-01 00:00:00

abstract：:Cluster headache (CH) is a short-lasting unilateral headache associated with ipsilateral craniofacial autonomic manifestations. A positron emission tomography (PET) study has shown that the posterior hypothalamus is activated during CH attacks, suggesting that hypothalamic hyperactivity plays a key role in CH pathophy...

journal_title：Therapeutic advances in neurological disorders

authors： Leone M,Franzini A,Cecchini AP,Broggi G,Bussone G

更新日期：2010-05-01 00:00:00

abstract：Introduction:Wernicke encephalopathy (WE) and Wernicke-Korsakoff syndrome (WKS) are well-known disorders caused by thiamine deficiency. In addition to the classical concept of these diseases, some literature data suggest a connection between mitochondrial dysfunction and WE/WKS. Psychotic disorders and WKS seem to run ...

journal_title：Therapeutic advances in neurological disorders

authors： Jimoh IJ,Sebe B,Balicza P,Fedor M,Pataky I,Rudas G,Gal A,Inczedy-Farkas G,Nemeth G,Molnar MJ

更新日期：2020-07-30 00:00:00